https://mindmedicinelaw.com/briefing/psychological-mechanisms-in-psychedelic-assisted-therapy-for-suds-2026-scoping-r-20260902-38065The Psychedelic Journalen2026-09-02T22:05:05.000247+00:00Psychological Mechanisms in Psychedelic-Assisted Therapy for SUDs: 2026 Scoping Reviewpsychedelic-assisted therapy, substance use disorders, psychological mechanisms, mystical experiences, clinical trials, integration protocols, FDA, causal mediation, identity transformation, emotional processinghttps://mindmedicinelaw.com/briefing/predictors-of-psilocybin-use-intentions-in-us-mental-health-care-20260901-38050The Psychedelic Journalen2026-09-02T22:06:30.862122+00:00Predictors of Psilocybin Use Intentions in US Mental Health Carepsilocybin use intentions, natural vs synthetic psychedelics, mental health treatment, clinical trial recruitment, patient preferences, public health messaging, demographic predictors, FDA approval, psychedelic policy, market accesshttps://mindmedicinelaw.com/briefing/molecular-enriched-fmri-advances-brain-age-prediction-in-neuroscience-20260901-38066The Psychedelic Journalen2026-09-02T22:06:21.163548+00:00Molecular-Enriched fMRI Advances Brain-Age Prediction in Neurosciencemolecular-enriched fMRI, brain-age prediction, neurotransmitter mapping, psychedelic clinical trials, biomarker development, dopamine system, serotonin system, neuroplasticity, MRI harmonization, functional connectivityhttps://mindmedicinelaw.com/briefing/mhcii-mediated-synaptic-pruning-in-dopaminergic-neurons-implications-for-neurode-20260901-38079The Psychedelic Journalen2026-09-02T22:06:12.287934+00:00MHCII-Mediated Synaptic Pruning in Dopaminergic Neurons: Implications for Neurodevelopmental Disordersmhc class ii, dopaminergic neurons, gabaergic synapses, neurodevelopmental disorders, maternal immune activation, synaptic pruning, neuroimmune mechanisms, psychedelic research, synaptic plasticityhttps://mindmedicinelaw.com/briefing/redefining-plasticity-in-psychedelic-neuroscience-research-20260901-38046The Psychedelic Journalen2026-09-02T22:05:53.185027+00:00Redefining 'Plasticity' in Psychedelic Neuroscience Researchpsychedelic therapy, neural plasticity, biomarkers, clinical trial design, regulatory science, mental health outcomes, MR-P framework, mechanistic research, translational neurosciencehttps://mindmedicinelaw.com/briefing/psilocybin-response-in-treatment-resistant-ocd-qualitative-insights-20260901-38048The Psychedelic Journalen2026-09-02T22:05:43.314343+00:00Psilocybin Response in Treatment-Resistant OCD: Qualitative Insightspsilocybin, treatment-resistant ocd, qualitative research, psychological engagement, surrender, self-compassion, emotional processing, clinical trials, therapist training, psychedelic therapyhttps://mindmedicinelaw.com/briefing/era-based-40-hz-assr-biomarkers-in-mood-and-psychotic-disorders-20260901-38088The Psychedelic Journalen2026-09-02T22:05:33.248031+00:00ERA-Based 40-Hz ASSR Biomarkers in Mood and Psychotic Disordersera systems, 40-hz assr, neural synchrony, biomarkers, mood disorders, psychotic disorders, psychedelic trials, precision psychiatry, gamma synchrony, clinical stratificationhttps://mindmedicinelaw.com/briefing/key-brain-circuit-underlies-ketamine-and-antidepressant-response-in-mice-20260901-38089The Psychedelic Journalen2026-09-02T22:05:15.546075+00:00Key Brain Circuit Underlies Ketamine and Antidepressant Response in Miceantidepressant mechanism, ketamine response, neural plasticity, infralimbic cortex, thalamic nucleus reuniens, ventral hippocampus, psychedelic drug development, circuit-based biomarkers, preclinical research, depression neurobiologyhttps://mindmedicinelaw.com/briefing/regulatory-and-methodological-gaps-in-ketamine-psilocybin-trials-20260901-38087The Psychedelic Journalen2026-09-02T22:04:54.239880+00:00Regulatory and Methodological Gaps in Ketamine & Psilocybin Trialsketamine, psilocybin, clinical trial design, regulatory challenges, depression, safety monitoring, participant diversity, informed consent, psychedelic research, policyhttps://mindmedicinelaw.com/briefing/psilocybin-crystal-structure-discovery-implications-for-research-20260901-37657The Psychedelic Journalen2026-09-01T15:05:39.203177+00:00Psilocybin Crystal Structure Discovery: Implications for Researchpsilocybin crystal structure, psychedelic research, molecular properties, clinical formulations, therapeutic mechanisms, stability of psilocybin, pharmaceutical development, regulatory implications, clinical trials, psychedelic medicinehttps://mindmedicinelaw.com/briefing/stanford-s-ketamine-ocd-study-explores-mu-opioid-mechanisms-20260901-37667The Psychedelic Journalen2026-09-01T15:05:22.977203+00:00Stanford's Ketamine OCD Study Explores Mu Opioid Mechanismsketamine, OCD treatment, mu opioid receptors, Stanford Psychiatry, psychiatric disorders, neurobiological pathways, clinical trials, psychedelic research, Carolyn Rodriguez, mental healthhttps://mindmedicinelaw.com/briefing/psychedelics-for-ptsd-depression-clinical-trial-evidence-and-gaps-20260831-38052The Psychedelic Journalen2026-09-02T22:06:03.432841+00:00Psychedelics for PTSD & Depression: Clinical Trial Evidence and Gapspsilocybin, mdma, ptsd, depression, clinical trials, therapist training, safety monitoring, regulatory policy, sample diversity, psychedelic-assisted therapyhttps://mindmedicinelaw.com/briefing/psychedelic-integration-in-healthcare-biomedical-and-existential-roles-20260831-37630The Psychedelic Journalen2026-09-01T15:06:39.057884+00:00Psychedelic Integration in Healthcare: Biomedical and Existential Rolespsychedelic research, biomedical applications, existential impacts, clinical trials, mental health treatment, public health strategies, regulatory frameworks, neuroplasticity, serotonin receptors, therapeutic protocolshttps://mindmedicinelaw.com/briefing/ketamine-and-psychotherapy-in-mental-health-treatment-20260831-37668The Psychedelic Journalen2026-09-01T15:06:20.605368+00:00Ketamine and Psychotherapy in Mental Health Treatmentketamine, psychotherapy, mental health treatment, synergistic effects, clinical trials, FDA guidelines, treatment protocols, depression therapy, neuroscience, psychotherapy integrationhttps://mindmedicinelaw.com/briefing/breathing-and-neural-oscillations-new-insights-in-neuroscience-20260831-37589The Psychedelic Journalen2026-09-01T15:06:07.331794+00:00Breathing and Neural Oscillations: New Insights in Neurosciencebreathing patterns, neural oscillations, brain-body interactions, mental health therapies, cognitive disorders, neuroscience research, respiration influence, therapeutic approacheshttps://mindmedicinelaw.com/briefing/philadelphia-s-public-health-response-to-medetomidine-20260831-37590The Psychedelic Journalen2026-09-01T15:05:52.926437+00:00Philadelphia's Public Health Response to Medetomidinemedetomidine, Philadelphia, opioid adulterant, public health response, overdose management, clinical recognition, community readiness, substance use treatment, drug supply monitoring, healthcare coordinationhttps://mindmedicinelaw.com/briefing/integrating-psychedelic-and-neuropsychiatric-therapies-a-new-framework-20260831-37581The Psychedelic Journalen2026-09-01T15:05:03.595615+00:00Integrating Psychedelic and Neuropsychiatric Therapies: A New Frameworkpsychedelic therapies, neuropsychiatric disorders, multidisciplinary framework, evidence-based treatment, mechanism of action, treatment protocolshttps://mindmedicinelaw.com/briefing/emerging-therapies-for-major-depressive-disorder-challenges-and-opportunities-20260830-37546The Psychedelic Journalen2026-09-01T15:07:23.126239+00:00Emerging Therapies for Major Depressive Disorder: Challenges and Opportunitiesmajor depressive disorder, treatment-resistant depression, neuroplasticity, neurocircuitry, SSRIs, TCAs, mental health treatment, psychiatric therapies, clinical trials, FDAhttps://mindmedicinelaw.com/briefing/mechanisms-of-clbp-and-mdd-comorbidity-implications-for-precision-medicine-20260830-37592The Psychedelic Journalen2026-09-01T15:07:03.112631+00:00Mechanisms of CLBP and MDD Comorbidity: Implications for Precision Medicinechronic low back pain, major depressive disorder, neural-immune interactions, gut-brain axis, precision medicine, clinical trials, neuroinflammation, spinal cord stimulation, electroacupuncture, comorbidity mechanismshttps://mindmedicinelaw.com/briefing/optimizing-ketamine-infusion-for-bipolar-depression-key-insights-20260830-37593The Psychedelic Journalen2026-09-01T15:06:50.459085+00:00Optimizing Ketamine Infusion for Bipolar Depression: Key Insightsketamine infusion, bipolar depression, treatment-resistant, individualized strategies, predictors of response, neurocognitive outcomes, inflammatory correlates, maintenance planning, clinical trials, mental health treatmenthttps://mindmedicinelaw.com/briefing/5-meo-dmt-s-potential-in-treating-depression-a-new-frontier-20260827-37829The Psychedelic Journalen2026-09-01T22:04:04.539910+00:005-MeO-DMT's Potential in Treating Depression: A New Frontier5-MeO-DMT, treatment-resistant depression, psychedelic therapy, serotonin receptors, psychedelic research, mental health treatment, regulatory considerations, clinical trials, safety and efficacy, psychological experienceshttps://mindmedicinelaw.com/briefing/ketamine-uropathy-clinical-policy-and-research-implications-global-2026-20260821-37999The Psychedelic Journalen2026-09-02T15:04:24.858778+00:00Ketamine Uropathy: Clinical, Policy, and Research Implications (Global, 2026)ketamine uropathy, psychedelic policy, urological complications, clinical monitoring, treatment risks, public health, patient consent, adverse events, NMDA receptor, regulatory guidance